Reference
1. Abdullahi H, Elnahas A, Konje JC. Seasonal influenza during
pregnancy. Eur J Obstet Gynecol Reprod Biol 2021; 258: 235-39.
2. Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy
as a risk factor for severe outcomes from influenza virus infection: A
systematic review and meta-analysis of observational studies. Vaccine
2017; 35: 521-28.
3. Wang R, Yan W, Du M, Tao L, Liu J. The effect of influenza virus
infection on pregnancy outcomes: A systematic review and meta-analysis
of cohort studies. Int J Infect Dis 2021; 105: 567-78.
4. CfDCa P. Updated Interim Recommendations for Obstetric Health Care
Providers Related to Use of Antiviral Medications in the Treatment and
Prevention of Influenza for the 2009–2010 Season. Accessed October 10,
2010.
5. Havers F, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, Jackson
LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA,
Eng HF, Lamerato L, Campbell AP, Fry AM. Use of influenza antiviral
medications among outpatients at high risk for influenza-associated
complications during the 2013-2014 influenza season. Clin Infect Dis
2015; 60: 1677-80.
6. Berveiller P, Mir O, Vinot C, Bonati C, Duchene P, Giraud C, Gil S,
Treluyer JM. Transplacental transfer of oseltamivir and its metabolite
using the human perfused placental cotyledon model. Am J Obstet Gynecol
2012; 206: 92.e1-6.
7. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu)
and its potential for use in the event of an influenza pandemic. J
Antimicrob Chemother 2005; 55 Suppl 1: i5-i21.
8. Meijer WJ, Bruinse HW, van den Broek MP, Kromdijk W, Wensing AM.
Oseltamivir and its active metabolite cross the placenta at significant
levels. Clin Infect Dis 2012; 54: 1676-7.
9. Minakami H, Kubo T, Nakai A, Saito S, Unno N. Pregnancy outcomes of
women exposed to laninamivir during pregnancy. Pharmacoepidemiol Drug
Saf 2014; 23: 1084-7.
10. Saito S, Minakami H, Nakai A, Unno N, Kubo T, Yoshimura Y. Outcomes
of infants exposed to oseltamivir or zanamivir in utero during pandemic
(H1N1) 2009. Am J Obstet Gynecol 2013; 209: 130.e1-9.
11. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito
S. Safety of neuraminidase inhibitors against novel influenza A (H1N1)
in pregnant and breastfeeding women. CMAJ 2009; 181: 55-8.
12. Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in
pregnancy: a review of preclinical and clinical data. Drug Saf 2010; 33:
631-42.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D,
Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational
studies in epidemiology: a proposal for reporting. Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:
2008-12.
14. Higgins JP. Cochrane handbook for systematic reviews of
interventions version 5.1.0. The Cochrane collaboration. Available at:
www.cochrane-handbook.org [6 December 2014]. 2014.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Stat Med 2002; 21: 1539-58.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997; 315: 629-34.
18. Greer LG, Sheffield JS, Rogers VL, Roberts SW, McIntire DD, Wendel
GD, Jr. Maternal and neonatal outcomes after antepartum treatment of
influenza with antiviral medications. Obstet Gynecol 2010; 115: 711-16.
19. Svensson T, Granath F, Stephansson O, Kieler H. Birth outcomes among
women exposed to neuraminidase inhibitors during pregnancy.
Pharmacoepidemiol Drug Saf 2011; 20: 1030-4.
20. Xie HY, Yasseen Iii AS, Xie RH, Fell DB, Sprague AE, Liu N, Smith
GN, Walker MC, Wen SW. Infant outcomes among pregnant women who used
oseltamivir for treatment of influenza during the H1N1 epidemic.
American Journal of Obstetrics and Gynecology 2013; 208: 293.e1-93.e7.
21. Beau AB, Hurault-Delarue C, Vial T, Montastruc JL, Damase-Michel C,
Lacroix I. Safety of oseltamivir during pregnancy: A comparative study
using the EFEMERIS database. BJOG: An International Journal of
Obstetrics and Gynaecology 2014; 121: 895-900.
22. Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SHL. Pregnancy
outcome following maternal use of zanamivir or oseltamivir during the
2009 influenza A/H1N1 pandemic: A national prospective surveillance
study. BJOG: An International Journal of Obstetrics and Gynaecology
2014; 121: 901-06.
23. Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K,
Hviid A, Håberg SE, Mølgaard-Nielsen D, Pasternak B, Kieler H.
Neuraminidase inhibitors during pregnancy and risk of adverse neonatal
outcomes and congenital malformations: Population based European
register study. BMJ 2017; 356.
24. Ehrenstein V, Kristensen NR, Monz BU, Clinch B, Kenwright A,
Sørensen HT. Oseltamivir in pregnancy and birth outcomes 11 Medical and
Health Sciences 1117 Public Health and Health Services. BMC Infectious
Diseases 2018; 18.
25. Chambers CD, Johnson D, Xu R, Luo Y, Jones KL. Oseltamivir use in
pregnancy: Risk of birth defects, preterm delivery, and small for
gestational age infants. Birth Defects Research 2019; 111: 1487-93.
26. Abraham K, Abraham A, Regi A, Lionel J, Thomas E, Vijayaselvi R,
Jeyaseelan L, Abraham AM, Santhanam S, Kuruvilla KA, Steinhoff MC.
Maternal and Perinatal Outcomes of Influenza in Pregnancy after
Treatment with Oseltamivir. J Glob Infect Dis 2021; 13: 20-26.
27. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a
systematic review and meta-analysis. Hum Reprod 2014; 29: 809-23.